BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 17704261)

  • 21. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
    Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
    Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.
    Gilks CB; Ionescu DN; Kalloger SE; Köbel M; Irving J; Clarke B; Santos J; Le N; Moravan V; Swenerton K;
    Hum Pathol; 2008 Aug; 39(8):1239-51. PubMed ID: 18602670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.
    Schwartz DR; Kardia SL; Shedden KA; Kuick R; Michailidis G; Taylor JM; Misek DE; Wu R; Zhai Y; Darrah DM; Reed H; Ellenson LH; Giordano TJ; Fearon ER; Hanash SM; Cho KR
    Cancer Res; 2002 Aug; 62(16):4722-9. PubMed ID: 12183431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
    Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
    APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ovarian cancer update: lessons from morphology, molecules, and mice.
    Cho KR
    Arch Pathol Lab Med; 2009 Nov; 133(11):1775-81. PubMed ID: 19886711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Origins and molecular pathology of ovarian cancer.
    Bell DA
    Mod Pathol; 2005 Feb; 18 Suppl 2():S19-32. PubMed ID: 15761464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells.
    Kao YC; Lin MC; Lin WC; Jeng YM; Mao TL
    Histopathology; 2012 Nov; 61(5):760-8. PubMed ID: 22747504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study.
    Köbel M; Kalloger SE; Baker PM; Ewanowich CA; Arseneau J; Zherebitskiy V; Abdulkarim S; Leung S; Duggan MA; Fontaine D; Parker R; Huntsman DG; Gilks CB
    Am J Surg Pathol; 2010 Jul; 34(7):984-93. PubMed ID: 20505499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
    Gurung A; Hung T; Morin J; Gilks CB
    Histopathology; 2013 Jan; 62(1):59-70. PubMed ID: 23240670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
    Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
    Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma.
    Takai N; Miyazaki T; Nishida M; Nasu K; Miyakawa I
    Int J Mol Med; 2002 Aug; 10(2):211-6. PubMed ID: 12119561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrin-linked kinase expression increases with ovarian tumour grade and is sustained by peritoneal tumour fluid.
    Ahmed N; Riley C; Oliva K; Stutt E; Rice GE; Quinn MA
    J Pathol; 2003 Oct; 201(2):229-37. PubMed ID: 14517840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention.
    Nezhat FR; Apostol R; Nezhat C; Pejovic T
    Am J Obstet Gynecol; 2015 Sep; 213(3):262-7. PubMed ID: 25818671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian surface epithelial neoplasms in the pediatric population: incidence, histologic subtype, and natural history.
    Hazard FK; Longacre TA
    Am J Surg Pathol; 2013 Apr; 37(4):548-53. PubMed ID: 23388124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining.
    Kritpracha K; Hanprasertpong J; Chandeying V; Dechsukhum C; Geater A
    J Obstet Gynaecol Res; 2005 Jun; 31(3):268-76. PubMed ID: 15916666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical detection of ras p21 oncoprotein in undifferentiated and well-differentiated epithelial carcinomas of the human ovary.
    Kuwashima Y; Shisa H; Uehara T; Kurosumi M; Kobayashi Y; Tanuma J; Shiromizu K; Matsuzawa M; Kishi K
    Anticancer Res; 1995; 15(6B):2847-50. PubMed ID: 8669877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic significance of elongation factor eEF1A2 in ovarian cancer.
    Pinke DE; Kalloger SE; Francetic T; Huntsman DG; Lee JM
    Gynecol Oncol; 2008 Mar; 108(3):561-8. PubMed ID: 18164751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.